Signatur Biosciences
Signatur turns complex gene-expression tests, starting with breast cancer prognosis, into simple PCR tests that a local hospital lab can run in days.
Overview
Signatur Biosciences develops decentralised precision diagnostics that translate multi-gene expression signatures into PCR-based assays runnable in local hospital laboratories, with a first product for early breast cancer prognosis to guide chemotherapy decisions, cutting turnaround from weeks in a centralised laboratory to days at a fraction of the cost. The company is London-based and remains active in the YC directory; clinical validation data have not been published in a primary source found at the time of checking.
Funding
All startupsPages like this
not linked directly; found by shared links- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyLiyfe
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyREPROSENT
Shares Y Combinator and the tag yc.
- CompanyDigistain
Shares Y Combinator, HR-positive / HER2-negative breast cancer and the tag yc.
- CompanyCofactor Genomics
Shares Y Combinator, Companion diagnostics and the tag yc.
- CompanyClear Gene
Shares Y Combinator, HR-positive / HER2-negative breast cancer and the tag yc.
- CompanyNearWave
Shares Y Combinator, HR-positive / HER2-negative breast cancer and the tag yc.